These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 30175513)
1. Functional erythropoietin-hepcidin axis in recombinant human erythropoietin independent haemodialysis patients. Touzot M; Lefebvre T; Roux A; Maheas C; Ridel C; Puy H; Karim Z Nephrology (Carlton); 2019 Jul; 24(7):751-757. PubMed ID: 30175513 [TBL] [Abstract][Full Text] [Related]
2. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices. Trkulja V Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846 [TBL] [Abstract][Full Text] [Related]
3. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study. Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328 [TBL] [Abstract][Full Text] [Related]
4. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Vale L; Wallace S; MacLeod A Cochrane Database Syst Rev; 2002; (4):CD003895. PubMed ID: 12519614 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. Albertazzi A; Di Liberato L; Daniele F; Battistel V; Colombi L Int J Artif Organs; 1998 Jan; 21(1):12-8. PubMed ID: 9554820 [TBL] [Abstract][Full Text] [Related]
6. Administration of the same dose of epoetin-beta intravenously and subcutaneously to patients with renal anaemia. Steffensen GK; Stergaard O Scand J Urol Nephrol; 2011 Dec; 45(6):461-9. PubMed ID: 21736448 [TBL] [Abstract][Full Text] [Related]
7. A hepcidin-based approach for iron therapy in hemodialysis patients: A pilot study. Touzot M; Lefebvre T; Maheas C; Ridel C; Puy H; Karim Z Hemodial Int; 2020 Apr; 24(2):188-194. PubMed ID: 32048444 [TBL] [Abstract][Full Text] [Related]
8. Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients. El Said HW; Abou Seif KH; Ahmed YS; Abou Elleil HA; El Said TW; Behairy MA; Mohamed MM; Ahmed FA Nephrology (Carlton); 2018 Apr; 23(4):323-330. PubMed ID: 28130911 [TBL] [Abstract][Full Text] [Related]
9. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients. Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889 [TBL] [Abstract][Full Text] [Related]
10. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Pennington S; Vale L; Wallace S; MacLeod A Cochrane Database Syst Rev; 2001; (4):CD003266. PubMed ID: 11687180 [TBL] [Abstract][Full Text] [Related]
12. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis. Rubab Z; Amin H; Abbas K; Hussain S; Ullah MI; Mohsin S Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):19-25. PubMed ID: 25579711 [TBL] [Abstract][Full Text] [Related]
13. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia. Landau D; London L; Bandach I; Segev Y PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538 [TBL] [Abstract][Full Text] [Related]
14. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cody J; Daly C; Campbell M; Donaldson C; Khan I; Rabindranath K; Vale L; Wallace S; Macleod A Cochrane Database Syst Rev; 2005 Jul; (3):CD003266. PubMed ID: 16034896 [TBL] [Abstract][Full Text] [Related]
15. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia. Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412 [TBL] [Abstract][Full Text] [Related]
16. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Taylor JE; Peat N; Porter C; Morgan AG Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients. Harzallah A; Zouaghi K; Dridi A; Boubaker K; Beji S; Ayari M; El Younsi F; Moussa FB; Kheder A Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):78-82. PubMed ID: 25579720 [TBL] [Abstract][Full Text] [Related]
18. Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients. Takasawa K; Takaeda C; Maeda T; Ueda N Nutrients; 2014 Dec; 7(1):103-18. PubMed ID: 25551249 [TBL] [Abstract][Full Text] [Related]
19. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Petrulienė K; Žiginskienė E; Kuzminskis V; Nedzelskienė I; Bumblytė IA Medicina (Kaunas); 2017; 53(2):90-100. PubMed ID: 28416170 [TBL] [Abstract][Full Text] [Related]
20. The target hemoglobin content values of reticulocytes for efficient anemia improvement are achieved by low ferritin levels and moderate transferrin saturation: a retrospective observational study. Ogawa C; Tsuchiya K; Tomosugi N; Shimada K; Kanda F; Maeda K Hematology; 2020 Dec; 25(1):71-78. PubMed ID: 32009585 [No Abstract] [Full Text] [Related] [Next] [New Search]